Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the therapeutic bcg vaccines market?

Over the past few years, the market size for therapeutic bcg vaccines has seen robust growth. The market is projected to expand from $56.47 billion in 2024 to $59.66 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. The substantial growth during the historic period is likely due to government efforts aimed at tuberculosis control, manipulation of the immune system, worldwide immunization programs, bladder cancer treatment, investments in vaccine production, and the rise of drug-resistant tuberculosis strains.

What will be the therapeutic bcg vaccines market size in the future?

The market size of therapeutic bcg vaccines is set to witness significant growth in the coming years, predicted to reach a value of $77.17 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.6%. The expected growth during the forecast period can be attributed to expansion into new indications, intensified research on immunotherapy, worldwide efforts to combat emerging infectious diseases, regulatory backing for vaccine development, and a focus on eradicating tuberculosis. Key trends projected for the forecast period include advancements in vaccine technology, improving supply chain performance, market mergers and partnerships, boosted patient knowledge and awareness, alternative delivery methods, and tailored medicine approaches.

Get your therapeutic bcg vaccines market report here!

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

What main drivers are fueling expansion in the therapeutic bcg vaccines market?

The increase in global tuberculosis (TB) cases is fuelling the expansion of the therapeutic BCG vaccine market. Tuberculosis is a potentially hazardous infectious disease that primarily affects the lungs. It spreads from person to person when minute droplets of bacteria are released into the air through coughs or sneezes. BCG vaccines, which use weakened germs that don’t cause TB, are employed to boost the immune system’s ability to combat the infection. The vaccine consistently provides defense against the most deadly forms of TB, including adolescent TB meningitis. The use of therapeutic BCG vaccines has risen due to their ability to protect against tuberculosis and combat infections. For example, a report released by the UK Health Security Agency, a government body in the UK, in February 2024 showed that TB cases in England had seen a 10.7% rise in 2023, with 4,850 cases reported, compared to 4,380 in 2022. As such, the escalating global TB cases are driving the expansion of the therapeutic BCG vaccine market.

What key areas define the segmentation of the global therapeutic bcg vaccines market?

The therapeutic bcg vaccines market covered in this report is segmented –

1) By Type: Therapy BCG, Immune BCG

2) By Demographics: Pediatrics, Adults

3) By End Use: Hospitals, Clinics, Other End Users

Subsegments:

1) By Therapy BCG: Intravesical BCG, Injectable BCG

2) By Immune BCG: BCG For Immune Enhancement, BCG For Allergy Treatment

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9178&type=smp

Who are the dominant players expanding their reach in the therapeutic bcg vaccines market?

Major companies operating in the therapeutic bcg vaccines market include Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., Microgen, Taj Pharma Ltd., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, China Biotechnology Co Ltd., Bharat Biotech International Ltd., Biological E. Limited, Shanghai Institute of Biological Products Co. Ltd., Cipla Limited, Instituto Butantan

How are evolving market trends shaping therapeutic bcg vaccines Strategies?

The emergence of strategic alliances is a prevalent trend within the therapeutic BCG vaccine market. Establishing collaborations with leading companies within the sector has become a primary focus for those looking to maintain their market standing. A prominent example of this is ImmunityBio, a biotechnology company based in the US, who joined forces with Serum Institute of India, a biotechnology and biopharmaceutical firm, in May 2024. The alliance revolves around ensuring a consistent supply of the Bacillus Calmette-Guerin (BCG) vaccine that can be used for all types of cancer. The purpose of the partnership is to produce the standard BCG (sBCG) that has approval for use outside of the US, as well as a next-generation recombinant BCG (iBCG) that is currently being tested. This iBCG aims to be used in unison with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-PMLN) for approved and future purposes, depending on regulatory consent.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9178

Which regions are emerging as leaders in the therapeutic bcg vaccines market?

Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2024. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: